Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Zeynep Özdemir, Arzu Karakurt, Elif Taşlidere, Nigar Vardi, Mehmet Abdullah Alagöz, Hakan Parlakpinar, Harun Uslu & Harika Gözükara Bağ. (2022) Histological assessment of liver and stomach damage caused by pyridazinone derivative antidepressant agents. Biotechnic & Histochemistry 97:5, pages 355-362.
Read now
Read now
Michael A. Darracq, Alycia Clark, Lily Qian & F. Lee Cantrell. (2013) A retrospective review of isolated duloxetine-exposure cases. Clinical Toxicology 51:2, pages 106-110.
Read now
Read now
Stefan Wilhelm, Frank G Boess, Ulrich Hegerl, Roland Mergl, Michael Linden, Alexander Schacht & Edith Schneider. (2012) Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?. Expert Opinion on Drug Safety 11:5, pages 699-711.
Read now
Read now
Istvan Bitter, Dora Filipovits & Pal Czobor. (2011) Adverse reactions to duloxetine in depression. Expert Opinion on Drug Safety 10:6, pages 839-850.
Read now
Read now
Michelle J Ormseth, Anne E Eyler, Cara L Hammonds & Chad S Boomershine. (2010) Milnacipran for the management of fibromyalgia syndrome. Journal of Pain Research 3, pages 15-24.
Read now
Read now
Beth A. Pangallo, Qi Zhang, Durisala Desaiah, David G.S. Perahia, Michael J. Detke & Sidney H. Kennedy. (2010) Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials. Current Medical Research and Opinion 26:11, pages 2643-2651.
Read now
Read now
Cheryl L Wright, Scott D Mist, Rebecca L Ross & Kim D Jones. (2010) Duloxetine for the treatment of fibromyalgia. Expert Review of Clinical Immunology 6:5, pages 745-756.
Read now
Read now
Jerry A Hall, Fujun Wang, Tina M Myers Oakes, Barbara G Utterback, Antonio Crucitti & Nayan Acharya. (2010) Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opinion on Drug Safety 9:4, pages 525-537.
Read now
Read now
Steinar Hunskaar & Lina Kristin Welle-Nilsen. (2010) The market lifecycle of duloxetine for urinary incontinence in Norway. Acta Obstetricia et Gynecologica Scandinavica 89:2, pages 217-222.
Read now
Read now
Trevor R Norman & James S Olver. (2008) Duloxetine in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment 4:6, pages 1169-1180.
Read now
Read now
Madelaine M. Wohlreich, Nayan Acharya, Indiana Strombom, Louis Kuritzky, Michael Robinson, Alexandra N. Heinloth, Arie Regev & Joachim F. Wernicke. (2008) Answers to the Most Common Questions About the Hepatic Safety Profile of Duloxetine. Postgraduate Medicine 120:2, pages 111-118.
Read now
Read now
Articles from other publishers (73)
Stefanie Stoller, Scott Capozza, Paola Alberti, Maryam Lustberg & Ian R. Kleckner. (2023) Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care in Cancer 31:5.
Crossref
Crossref
Ian A. Jones, Arad Talehakimi, Linda S. Murphy, Jennifer C. Wang, Amit S. Piple, Alexander B. Christ & Nathanael D. Heckmann. (2023) Duloxetine for Postoperative Pain Control Following Knee or Hip Replacement: A Systematic Review and Meta-Analysis. Arthroplasty Today 20, pages 101097.
Crossref
Crossref
Camilla Rocchi, Massimiliano Valeriani & Rita Di Leo. 2023. Autonomic Disorders in Clinical Practice. Autonomic Disorders in Clinical Practice
335
351
.
Xuan Qin, John M. Hakenjos, Kevin R. MacKenzie, Mercedes Barzi, Hemantkumar Chavan, Pranavanand Nyshadham, Jin Wang, Sung Yun Jung, Joie Z. Guner, Si Chen, Lei Guo, Partha Krishnamurthy, Karl-Dimiter Bissig, Stephen Palmer, Martin M. Matzuk & Feng Li. (2022) Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice. Drug Metabolism and Disposition 50:2, pages 128-139.
Crossref
Crossref
Md. Tanvir Kabir, Nuzhat Tabassum, Md. Sahab Uddin, Faissal Aziz, Tapan Behl, Bijo Mathew, Md. Habibur Rahman, Raushanara Akter, Abdur Rauf & Lotfi Aleya. (2021) Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-20.
Crossref
Crossref
Uazman Alam, Gordon Sloan & Solomon Tesfaye. (2020) Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs. Drugs 80:4, pages 363-384.
Crossref
Crossref
Li Chen, Min Gong, Guoming Liu, Fei Xing, Jiaxin Liu & Zhou Xiang. (2019) Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta‐analysis of randomised controlled trials. Internal Medicine Journal 49:12, pages 1514-1523.
Crossref
Crossref
Yuma Yokoi, Atsuo Nakagawa, Naoki Yoshimura, Toshiaki A. Furukawa, Masaru Mimura, Akira Iwanami, Takayuki Abe & Kazuyuki Nakagome. (2019) Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second‐generation antidepressants: Study protocol for a randomized, parallel‐group, non‐inferiority trial. Neuropsychopharmacology Reports 39:4, pages 262-272.
Crossref
Crossref
Shin-ichi Konno, Levent Alev, Natsuko Oda, Toshimitsu Ochiai & Hiroyuki Enomoto. (2019) An Open-Label, 52-Week, Phase III Trial of Duloxetine in Japanese Patients with Chronic Low Back Pain. Pain Medicine 20:8, pages 1479-1488.
Crossref
Crossref
Atsushi Takayama, Takahiko Nagamine, Yoshinobu Matsumoto & Masaru Nakamura. (2019) Duloxetine and Angiotensin II Receptor Blocker Combination Potentially Induce Severe Hyponatremia in an Elderly Woman. Internal Medicine 58:12, pages 1791-1794.
Crossref
Crossref
Ting-Ting Zhang, Rui Xue, Shi-Yong Fan, Qiong-Yin Fan, Lei An, Juan Li, Lei Zhu, Yu-Hua Ran, Li-Ming Zhang, Bo-Hua Zhong, Yun-Feng Li, Cai-Ying Ye & You-Zhi Zhang. (2018) Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord. Journal of Neuroinflammation 15:1.
Crossref
Crossref
Joshua S. Mervis & Daniel G. Federman. (2018) Pain Management in Patients with Chronic Wounds. Current Dermatology Reports 7:3, pages 136-146.
Crossref
Crossref
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo & Naga Chalasani. 2018. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
844
890.e17
.
Ruhsen Öcal, Ceyda Tanoğlu, Seda Kibaroğlu, Eda Derle, Ufuk Can, Mahir Kirnap, Gökhan Moray & Mehmet Haberal. (2017) Prevalence and Treatment of Neuropathic Pain in Kidney and Liver Transplant Recipients. Experimental and Clinical Transplantation.
Crossref
Crossref
Andy Wolff, Revan Kumar Joshi, Jörgen Ekström, Doron Aframian, Anne Marie Lynge Pedersen, Gordon Proctor, Nagamani Narayana, Alessandro Villa, Ying Wai Sia, Ardita Aliko, Richard McGowan, Alexander Ross Kerr, Siri Beier Jensen, Arjan Vissink & Colin Dawes. (2016) A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs in R&D 17:1, pages 1-28.
Crossref
Crossref
Mélanie Kremer, Eric Salvat, André Muller, Ipek Yalcin & Michel Barrot. (2016) Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience 338, pages 183-206.
Crossref
Crossref
Nicholas J. Murphy, Jillian P. Eyles & David J. Hunter. (2016) Hip Osteoarthritis: Etiopathogenesis and Implications for Management. Advances in Therapy 33:11, pages 1921-1946.
Crossref
Crossref
Gabriel Perlemuter, Patrice Cacoub, Dominique Valla, Dominique Guyader, Barbara Saba, Cécile Batailler & Kevin Moore. (2016) Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients. CNS Drugs 30:9, pages 877-888.
Crossref
Crossref
Meredith R. Metcalf, Roger R. Dmochowski & Priya Padmanabhan. (2016) The Non-surgical Options for SUI—Is Any One Optimal?. Current Bladder Dysfunction Reports 11:1, pages 66-72.
Crossref
Crossref
Nasrin Dodangi, Nastaran Habibi & Ali Nazeri astaneh. (2015) Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder. Journal of Comprehensive Pediatrics 6:4.
Crossref
Crossref
Beth DeJongh, Kade Birkeland & Michael Brenner. (2015) Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm. American Journal of Cardiovascular Drugs 15:3, pages 171-184.
Crossref
Crossref
Dan Ziegler & Vivian Fonseca. (2015) From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. Journal of Diabetes and its Complications 29:1, pages 146-156.
Crossref
Crossref
Julie Myers, Ronald C Wielage, Baoguang Han, Karen Price, James Gahn, Marie-Ange Paget & Michael Happich. (2014) The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis. BMC Musculoskeletal Disorders 15:1.
Crossref
Crossref
Massimo Carlo Mauri, Alessio Fiorentini, Silvia Paletta & Alfredo Carlo Altamura. (2014) Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment. Clinical Pharmacokinetics 53:12, pages 1069-1081.
Crossref
Crossref
S. Fanoe, D. Kristensen, A. Fink-Jensen, H. K. Jensen, E. Toft, J. Nielsen, P. Videbech, S. Pehrson & H. Bundgaard. (2014) Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal 35:20, pages 1306-1315.
Crossref
Crossref
Michael PT Lunn, Richard AC Hughes & Philip J Wiffen. (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2015:10.
Crossref
Crossref
Dominique Larrey & Marie-Pierre Ripault. 2013. Drug-Induced Liver Disease. Drug-Induced Liver Disease
443
462
.
Vladimir Skljarevski, Elijah P. Frakes, Doron Sagman, Sarah Lipsius, Alexandra N. Heinloth & Héctor J. Dueñas Tentori. (2012) Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment 2012, pages 1-12.
Crossref
Crossref
Joel Raskin, Thomas George, Renee E. Granger, Nadia Hussain, George Weizhong Zhao & Lauren B. Marangell. (2012) Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: Outcomes following randomized switch to either duloxetine or escitalopram. Journal of Psychiatric Research 46:5, pages 667-674.
Crossref
Crossref
Nadine Attal. (2012) Neuropathic Pain. CONTINUUM: Lifelong Learning in Neurology 18, pages 161-175.
Crossref
Crossref
Herbert L. Bonkovsky, Dean P. Jones, Mark W. Russo & Steven I. Shedlofsky. 2012. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
417
461
.
A. Hartemann, N. Attal, D. Bouhassira, I. Dumont, H. Gin, S. Jeanne, G. Said & J.-L. Richard. (2011) Painful diabetic neuropathy: Diagnosis and management. Diabetes & Metabolism 37:5, pages 377-388.
Crossref
Crossref
A. Hartemann, N. Attal, D. Bouhassira, I. Dumont, H. Gin, S. Jeanne, G. Said & J.-L. Richard. (2011) Prise en charge de la polyneuropathie diabétique douloureuse. Médecine des Maladies Métaboliques 5:5, pages 1-34.
Crossref
Crossref
Mary Pat Knadler, Evelyn Lobo, Jill Chappell & Richard Bergstrom. (2011) Duloxetine. Clinical Pharmacokinetics 50:5, pages 281-294.
Crossref
Crossref
Agnès Hartemann, Nadine Attal, Didier Bouhassira, Isabelle Dumont, Henri Gin, Sandrine Jeanne, Gérard Said & Jean-Louis Richard. (2011) Prise en charge de la polyneuropathie diabétique douloureuse. Médecine des Maladies Métaboliques 5:2, pages 208-222.
Crossref
Crossref
Javad Mahmoudi-Gharaei, Nasrin Dodangi, Mehdi Tehrani-Doost & Toktam Faghihi. (2011) Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study. Human Psychopharmacology: Clinical and Experimental 26:2, pages 155-160.
Crossref
Crossref
Martin A. Katzman, Alex Copeland, Larry J. Klassen, Pratap Chokka & Olga Brawman-Mintzer. (2011) Pharmacotherapy for Generalized Anxiety Disorder. Psychiatric Annals 41:2, pages 95-103.
Crossref
Crossref
Philip J Mease, Peter J Zimetbaum, Mei Sheng Duh, Francis Vekeman, Annie Guérin, Mariette Boerstoel-Streefland, Wenjun Jiang & Patrick Lefebvre. (2017) Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Annals of Pharmacotherapy 45:2, pages 179-188.
Crossref
Crossref
Amy S. Chappell, Durisala Desaiah, Hong Liu‐Seifert, Shuyu Zhang, Vladimir Skljarevski, Yuri Belenkov & Jacques P. Brown. (2011) A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee. Pain Practice 11:1, pages 33-41.
Crossref
Crossref
R. Vuppalanchi, P. H. Hayashi, N. Chalasani, R. J. Fontana, H. Bonkovsky, R. Saxena, D. Kleiner & J. H. Hoofnagle. (2010) Duloxetine hepatotoxicity: a case‐series from the drug‐induced liver injury network. Alimentary Pharmacology & Therapeutics 32:9, pages 1174-1183.
Crossref
Crossref
Nils Erik Gilhus, Michael P. Barnes & Michael BraininN. Attal, G. Cruccu, R. Baron, M. Haanpää, P. Hansson, T. S. Jensen & T. Nurmikko. 2010. European Handbook of Neurological Management. European Handbook of Neurological Management
399
410
.
N. Attal, G. Cruccu, R. Baron, M. Haanpää, P. Hansson, T. S. Jensen & T. Nurmikko. (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 17:9, pages 1113.
Crossref
Crossref
Takeya Kitta, Minoru Miyazato, Michael B. Chancellor, William C. de Groat, Katsuya Nonomura & Naoki Yoshimura. (2010) α2-Adrenoceptor Blockade Potentiates the Effect of Duloxetine on Sneeze Induced Urethral Continence Reflex in Rats. The Journal of Urology 184:2, pages 762-768.
Crossref
Crossref
Laurence A. Bradley, Madelaine M. Wohlreich, Fujun Wang, Paula J. Gaynor, Michael J. Robinson, Deborah N. D'Souza & Philip J. Mease. (2010) Pain Response Profile of Patients With Fibromyalgia Treated With Duloxetine. The Clinical Journal of Pain 26:6, pages 498-504.
Crossref
Crossref
Philip J. Mease, I. Jon Russell, Daniel K. Kajdasz, Curtis G. Wiltse, Michael J. Detke, Madelaine M. Wohlreich, Daniel J. Walker & Amy S. Chappell. (2010) Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia. Seminars in Arthritis and Rheumatism 39:6, pages 454-464.
Crossref
Crossref
Lesley M. Arnold. (2010) The Pathophysiology, Diagnosis and Treatment of Fibromyalgia. Psychiatric Clinics of North America 33:2, pages 375-408.
Crossref
Crossref
Stephen Brunton, Fujun Wang, S. Beth Edwards, Antonio S. Crucitti, Melissa J. Ossanna, Daniel J. Walker & Michael J. Robinson. (2010) Profile of Adverse Events with Duloxetine Treatment. Drug Safety 33:5, pages 393-407.
Crossref
Crossref
K. Kelin, M. Berk, M. Spann, D. Sagman, J. Raskin, D. Walker & D. Perahia. (2010)
Duloxetine 60 mg/day for the prevention of depressive recurrences:
post hoc
analyses from a recurrence prevention study
. International Journal of Clinical Practice 64:6, pages 719-726.
Crossref
Crossref
JAIME C. BRANCO, OLOF ZACHRISSON, SERGE PERROT & YVES MAINGUY. (2010) A European Multicenter Randomized Double-blind Placebo-controlled Monotherapy Clinical Trial of Milnacipran in Treatment of Fibromyalgia. The Journal of Rheumatology 37:4, pages 851-859.
Crossref
Crossref
Adam Stępień & Teofan M. Domżał. (2010) Nowe wytyczne dotyczące leczenia bólu neuropatycznego. Neurologia i Neurochirurgia Polska 44:5, pages 437-442.
Crossref
Crossref
Jill Chappell, Jingsong He, Mary Pat Knadler, Malcolm Mitchell, Douglas Lee & Evelyn Lobo. (2013) Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects. The Journal of Clinical Pharmacology 49:12, pages 1456-1466.
Crossref
Crossref
Amy S. Chappell, Melissa J. Ossanna, Hong Liu-Seifert, Smriti Iyengar, Vladimir Skljarevski, Linda Chunhong Li, Robert M. Bennett & Harry Collins. (2009) Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain 146:3, pages 253-260.
Crossref
Crossref
Michael PT Lunn, Richard AC Hughes & Philip J Wiffen. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
V. Skljarevski, M. Ossanna, H. Liu-Seifert, Q. Zhang, A. Chappell, S. Iyengar, M. Detke & M. Backonja. (2009) A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. European Journal of Neurology 16:9, pages 1041-1048.
Crossref
Crossref
Joachim F. Wernicke, Apurva Prakash, Daniel K. Kajdasz & John Houston. (2009) Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. Journal of Diabetes and its Complications 23:5, pages 349-359.
Crossref
Crossref
Ernest H. S. Choy, Philip J. Mease, Daniel K. Kajdasz, Madelaine M. Wohlreich, Paul Crits-Christoph, Daniel J. Walker & Amy S. Chappell. (2009) Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clinical Rheumatology 28:9, pages 1035-1044.
Crossref
Crossref
Lesley Arnold. 2009. Fibromyalgia. Fibromyalgia
56
80
.
Monique P. Curran. (2009) Duloxetine. Drugs 69:9, pages 1217-1227.
Crossref
Crossref
Eric SerraMichel Andrejak. (2009) Pharmacotherapy of Fibromyalgia: Focus on Duloxetine. Clinical Medicine. Therapeutics 1, pages CMT.S1162.
Crossref
Crossref
Martin A. Katzman. (2009) Current Considerations in the Treatment of Generalized Anxiety Disorder. CNS Drugs 23:2, pages 103-120.
Crossref
Crossref
Evelyn D. Lobo, Tonya Quinlan, Lisa OʼBrien, Mary Pat Knadler & Michael Heathman. (2009) Population Pharmacokinetics of Orally Administered Duloxetine in Patients. Clinical Pharmacokinetics 48:3, pages 189-197.
Crossref
Crossref
Daniel J. Clauw, Philip Mease, Robert H. Palmer, R. Michael Gendreau & Yong Wang. (2008) Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics 30:11, pages 1988-2004.
Crossref
Crossref
Jon I. Russell, Philip J. Mease, Timothy R. Smith, Daniel K. Kajdasz, Madelaine M. Wohlreich, Michael J. Detke, Daniel J. Walker, Amy S. Chappell & Lesley M. Arnold. (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial ☆. Pain 136:3, pages 432-444.
Crossref
Crossref
Rajnish Mago, Rajeev Mahajan & Michael E. Thase. (2008) Medically serious adverse effects of newer antidepressants. Current Psychiatry Reports 10:3, pages 249-257.
Crossref
Crossref
Michael PT Lunn, Richard AC Hughes & Philip J Wiffen. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Joel Raskin, Curtis G. Wiltse, James J. Dinkel, Daniel J. Walker, Durisala Desaiah & Cornelius Katona. (2008) Safety and Tolerability of Duloxetine at 60 mg Once Daily in Elderly Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology 28:1, pages 32-38.
Crossref
Crossref
Patrick J. Barry, Paul Gallagher & Cristin Ryan. (2008) Inappropriate prescribing in geriatric patients. Current Psychiatry Reports 10:1, pages 37-43.
Crossref
Crossref
Cathrine Baastrup & Nanna B Finnerup. (2008) Pharmacological Management of Neuropathic Pain Following Spinal Cord Injury. CNS Drugs 22:6, pages 455-475.
Crossref
Crossref
Evelyn D Lobo, Richard F Bergstrom, Shobha Reddy, Tonya Quinlan, Jill Chappell, Quan Hong, Barbara Ring & Mary Pat Knadler. (2008) In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine. Clinical Pharmacokinetics 47:3, pages 191-202.
Crossref
Crossref
Evelyn D Lobo, Corina Loghin, Mary Pat Knadler, Tonya Quinlan, Lu Zhang, Jill Chappell, Richard Lucas & Richard F Bergstrom. (2008) Pharmacokinetics of Duloxetine in Breast Milk and Plasma of Healthy Postpartum Women. Clinical Pharmacokinetics 47:2, pages 103-109.
Crossref
Crossref
William P CheshireJrJr & Robert D Fealey. (2008) Drug-Induced Hyperhidrosis and Hypohidrosis. Drug Safety 31:2, pages 109-126.
Crossref
Crossref
David A. Fishbain. (2007) Duloxetine Status. Pain Medicine 8:suppl 2, pages S25-S26.
Crossref
Crossref
. (2007) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 16:8, pages i-xii.
Crossref
Crossref